NeoVista Announces First Commercial Utilization of Epimacular Brachytherapy in Germany to Treat Wet AMD
February 2, 2011
NeoVista recently announced today the first commercial utilization in Germany of Epimacular Brachytherapy using the VIDION ANV Therapy system as an adjunct therapy to anti-VEGF injections for the treatment of neovascular age-related macular degeneration.
NeoVista’s beta radiation therapy affects the abnormal blood vessels of wet AMD by slowing the development of new vessels and reducing inflammation, allowing the macula to return to its normal position. The treatment being used utilizes a typical vitrectomy, with radiation delivered using the NeoVista system. Radiation delivery using the NeoVista device is highly focal, penetrating the target area to a depth of only 3 mm and covering an area slightly larger than 5 mm in diameter. Because beta radiation dissipates very rapidly, surrounding normal tissues are less affected than with other forms of radiation used in older treatments.
For further information, read Irv Aron’s detailed review of NeoVista’s approach to treatment of AMD with radiation therapy.
Comments
Jump down to form below to submit your own comments
